Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLYMNYSE:CVMNASDAQ:JMACNASDAQ:OCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLYMClimb Bio$1.21+0.8%$1.28$1.05▼$10.86$81.77M-0.12304,292 shs588,709 shsCVMCEL-SCI$0.24-1.8%$0.26$0.18▼$2.39$20.34M0.51.07 million shs554,087 shsJMACMaxpro Capital Acquisition$6.09-2.1%$6.80$7.50▼$19.22$145.16M0.0174,040 shs16,158 shsOCXOncoCyte$2.83-2.1%$3.18$1.92▼$4.75$80.88M0.9557,102 shs26,673 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLYMClimb Bio-4.00%-4.76%+2.56%-36.84%+119,999,900.00%CVMCEL-SCI-2.03%-15.10%+13.93%-38.30%-85.69%JMACMaxpro Capital Acquisition-2.14%-4.84%+1.50%-28.35%-43.66%OCXOncoCyte-1.03%-7.37%+4.33%+33.80%+4.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLYMClimb BioN/AN/AN/AN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AOCXOncoCyte2.152 of 5 stars3.32.00.00.01.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLYMClimb Bio 3.50Strong Buy$10.00726.45% UpsideCVMCEL-SCI 0.00N/AN/AN/AJMACMaxpro Capital Acquisition 0.00N/AN/AN/AOCXOncoCyte 2.67Moderate Buy$4.4256.18% UpsideCurrent Analyst Ratings BreakdownLatest CVM, CLYM, JMAC, and OCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.253/28/2025OCXOncoCyteLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.003/25/2025OCXOncoCyteStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$4.00 ➝ $4.003/25/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.25(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLYMClimb BioN/AN/AN/AN/A$3.90 per shareN/ACVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AOCXOncoCyte$1.88M43.00N/AN/A$2.48 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLYMClimb Bio-$35.12M-$2.13N/AN/AN/AN/A-42.21%-41.39%5/21/2025 (Estimated)CVMCEL-SCI-$26.92M-$0.48N/AN/AN/AN/A-238.05%-104.65%N/AJMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AOCXOncoCyte-$27.78M-$4.40N/AN/AN/A-6,122.29%-269.32%-59.71%5/13/2025 (Estimated)Latest CVM, CLYM, JMAC, and OCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025CLYMClimb Bio-$0.15N/AN/AN/AN/AN/A3/25/2025Q4 2024CLYMClimb Bio-$0.15-$0.13+$0.02-$0.13N/AN/A3/24/2025Q4 2024OCXOncoCyte-$0.40$0.48+$0.88-$1.93$0.16 million$1.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLYMClimb BioN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AOCXOncoCyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLYMClimb BioN/A57.7357.73CVMCEL-SCI0.661.071.09JMACMaxpro Capital AcquisitionN/AN/AN/AOCXOncoCyteN/A0.530.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLYMClimb Bio69.76%CVMCEL-SCI12.08%JMACMaxpro Capital Acquisition73.18%OCXOncoCyte55.35%Insider OwnershipCompanyInsider OwnershipCLYMClimb Bio3.20%CVMCEL-SCI16.24%JMACMaxpro Capital Acquisition19.27%OCXOncoCyte1.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLYMClimb Bio967.58 million65.07 millionN/ACVMCEL-SCI4384.12 million64.67 millionOptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableOCXOncoCyte12028.60 million17.18 millionNo DataCVM, CLYM, JMAC, and OCX HeadlinesRecent News About These CompaniesOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7 at 4:10 PM | globenewswire.comOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7 at 4:08 PM | prismmediawire.comWhy OncoCyte Corporation’s (OCX) Stock Is Up 5.11%May 7 at 2:19 AM | aaii.comBest Momentum Stocks to Buy for May 6thMay 6 at 11:00 AM | zacks.comNew Strong Buy Stocks for May 6thMay 6 at 8:45 AM | zacks.comOncoCyte (NASDAQ:OCX) Trading Down 3.1% - Here's What HappenedMay 2, 2025 | marketbeat.comOncocyte Corporation: Oncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | finanznachrichten.deOncocyte study links blood test to kidney rejection markersApril 30, 2025 | investing.comOncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | globenewswire.comOncocyte’s Proprietary Assay Demonstrates Long-Term Clinical ValidityApril 29, 2025 | taiwannews.com.twOncocyte's Proprietary Assay Demonstrates Long-Term Clinical ValidityApril 29, 2025 | globenewswire.comWhy OncoCyte Corporation’s (OCX) Stock Is Up 12.22%April 25, 2025 | aaii.comNew Strong Buy Stocks for April 24thApril 24, 2025 | zacks.comWhy OncoCyte Corporation’s (OCX) Stock Is Up 6.85%April 16, 2025 | aaii.comOncoCyte (NASDAQ:OCX) Receives Buy Rating from Needham & Company LLCApril 10, 2025 | marketbeat.comStockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)April 8, 2025 | marketbeat.comOncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?April 7, 2025 | zacks.comOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | prismmediawire.comOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comOncoCyte files to sell 10.61M shares of common stock for holdersApril 1, 2025 | markets.businessinsider.comOncoCyte initiated with a Buy at Lake StreetMarch 29, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVM, CLYM, JMAC, and OCX Company DescriptionsClimb Bio NASDAQ:CLYM$1.21 +0.01 (+0.83%) As of 04:00 PM EasternClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.CEL-SCI NYSE:CVM$0.24 0.00 (-1.79%) Closing price 04:00 PM EasternExtended Trading$0.24 0.00 (-0.33%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Maxpro Capital Acquisition NASDAQ:JMAC$6.09 -0.13 (-2.14%) As of 05/5/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.OncoCyte NASDAQ:OCX$2.83 -0.06 (-2.15%) Closing price 03:59 PM EasternExtended Trading$2.83 +0.00 (+0.07%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
